As the growing demand for personalised medicines continues, a recent report projects that the global growth of the Advanced Therapy Medical Products (ATMPs) market will also be boosted.
This creates tremendous potential for patients and the industry alike.
Currently there are a small number of licensed products, with many more undergoing clinical trials. In addition to this, there are numerous projects in late phase development about to enter the clinical trial phase.
Cambridge, UK and Milpitas, USA - 30 January 2020 - Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell, Inc. (ASC) for life science research and diagnostic markets. ASC is a long-established leader in the edited cell lines market, focused on developing genome editing technologies into novel therapeutics to advance drug discovery.
AMSBIO announces a Custom Chimeric Antigen Receptor T cell (CAR-T) service designed to take advantage of the astonishing clinical breakthroughs achieved with CAR-T cells in various hematological malignancies.
Cambridge, UK, 28 January 2020 Mogrify Ltd (Mogrify™), a UK company aiming to transform the development of cell therapies, today announced that it has secured $1.1M of additional funding from SBRI Healthcare, the NHS England funded initiative championed by the Academic Health Science Network (AHSN), to assess its regenerative cartilage therapy, for the treatment of cartilage defects, osteoarthritis and other musculoskeletal conditions, before entering clinical trials.
Westbury, NY – Jan. 27, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has been selected by upcyte® technologies GmbH as the exclusive commercial worldwide distributor of its cell products and media, including cells derived from hepatocytes and liver sinusoidal endothelial cells (LSECs).
Sandwich, Kent, UK, January 22 2020 – Over 200 local school pupils have taken part in unique hands-on scientific learning opportunities at Discovery Park since the relaunch of its Community Lab last year. As is clear from the Community Lab January 2020 Impact Report, published today, students and teachers alike have been inspired by the activities, established to encourage children to adopt scientific careers and grow the local STEM1 skills base.
Cambridge, UK, 21 January 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it will license its gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line to NGM Biopharmaceuticals, Inc. (“NGM”) (Nasdaq: NGM).
Cambridge, UK, 21 January: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed that it has entered into a commercial agreement with CCL, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK, Ireland (non-exclusive), the Middle East and the Balkans (exclusively).
Under the agreement, Cambridge based CCL will manage and facilitate the fulfilment of orders of PredictSURE IBD™, as well as receive and process all samples.
Cambridge, UK, 21 January 2020: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project collaboration with Otsuka Pharmaceutical Co., the world-leading pharmaceutical company dedicated to the research and development of highly-innovative drugs and diagnostics. Financial details of the agreement are not disclosed.